Sign Out
Insulin-dependent (type I) diabetes (e.g., diabetics with a history of ketonemia), diabetic ketonemia, diabetic coma or precoma, acute or chronic metabolic acidosis.
Known hypersensitivity to any of the excipients of this drug, sulfonylureas, sulfonamides, or biguanide.
There is no experience in patients with severe hepatic dysfunction or hemodialysis. In case of severe hepatic or renal function disorders, a change-over to insulin is required to achieve adequate control of blood glucose.
Pregnant women, women of child-bearing potential, nursing mother.
Patients susceptible to lactic acidosis, patients with a history of lactic acidosis, renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥1.5 mg/dL [males], ≥1.4 mg/dL [females], or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia.
This drug should be temporarily discontinued in patients being administered iodinated contrast materials intravenously, because use of such products may result in acute alteration of renal function. (See Warnings and Precautions.)
Severe infections, before and after surgery, serious trauma.
Malnourished, starving, or debilitated patients, or patients with pituitary or adrenal insufficiency.
Hepatic dysfunction, severe lung dysfunction, other condition likely to be with hypoxemia, excessive alcohol intake, dehydration, gastrointestinal disturbance including diarrhea and vomiting.
Congestive heart failure requiring pharmacologic treatment.
